SAN FRANCISCO, USA – IDEA Pharma, the leading Path-to-Market design practice, today unveiled an ambitious June schedule; a triple-header of executive events scheduled at the marquee pharmaceutical and biotech events.
The company kicks-off the month hosting the next of their acclaimed Future of Pharma panel discussion series on June 7th, coinciding with BIO International in San Francisco, CA. The evening event will focus on patient-centered design, with an esteemed panel comprising Genentech’s Global Head of Outcomes Research for Oncology, Alicyn Campbell; Otsuka’s Senior VP of Clinical Management & Business Operations, Margaretta Nyilas, MD; and Head of Janssen’s Disease Interception Accelerator, Ben Wiegand.
Commenting on the launch of the event, IDEA Pharma’s CEO, Mike Rea, said “We were taken aback by the popularity of the first Future of Pharma event, held during J.P. Morgan in January – providing space for senior pharma executives to think, and engage, is an old idea, but one lost in most meetings, it seems. Patient-centered design isn’t about making patients want what you launch; it is about developing and launching what patients want, so it is hard to think of a more appropriate subject for all of our futures. We have once again been fortunate to be joined by our respected and long term collaborators from Janssen and Otsuka, and we welcome Genentech to the panel”.
Secondly, during BIO International, Mike Rea will join organizer Melinda Richter (Head of JLABS) and industry thought leader, Bernard Munos, on another panel to discuss “Innovation: Locking in the Freshness”. This talk on June 8th will look at “improving our understanding of innovation and the various factors that allow us to harness it for breakthrough solutions”. Or in Mike’s words, “understanding what innovation is (and therefore how it can be measured) and how to harness it for breakthrough medicines”. link
And lastly, the company will be on attending the American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 2nd to 6th) to discuss the advances in oncology presenting new and complex path-to-market challenges, as well as opportunities, for pharma clients. Commenting on the opportunity, John Tonra (Managing Director) said “here at IDEA Pharma we are proud of our record of success in partnering with our clients to design great assets across the oncology spectrum. In fact, IDEA Pharma has provided path-to-market support for 7 of the top 10 projected oncology assets by 2020, including leading brands such as OpdivoTM, AvastinTM, ImbruvicaTM, and RevlimidTM. We look forward to partnering at ASCO with our clients and creating the next iconic oncology brand!”.
10 months ago
Mike Rea CEO @ IDEA Pharma
Alicyn Campbell Global Head of Outcomes Research for Oncology @ Genentech
Margaretta Nyilas MD
Ben Wiegand Head of Disease Interception Accelerator @ Janssen